微量中药成分的起效机制研究不容忽视--“遗传协同致死”模式有助于发现并阐释中药显效物质基础及起效机制

The Mechanism Study of Micro-substance of Chinese Medicine——The Discovery and Elucidation of Effective Substance and Mechanism of Chinese Medicine via the Theory of Synthetic Lethality

中药作用机制及显效物质的阐明是制约中药现代化进程的主要障碍。当前研究的对象大都为中药的丰度成分,研究思路多归为正向药理学模式,这种模式往往忽略对中药微量成分的研究。"遗传协同致死"是一种基因之间的互作关系,可使得共同调控生物效应呈现级数放大(大于1 000倍)。鉴于,遗传协同研究模式在抗肿瘤药物研发中取得喜人成绩。(包括PARP抑制剂的发现,化疗药物增效减毒组合的临床使用等)。同时,中药在对抗环境胁迫所产生的多种次生代谢产物,为契合遗传协同靶点提供多成分基础。那么,是否可以将这一研究模式用于阐明微量活性成分的研究?从"靶点-成分-效应"的逆向思维出发,在明确遗传协同靶点的基础上,对中药微量弱效成分起效机制展开研究,并进一步发现潜力的协同成分组合。

The elaboration of the mechanism and pharmacodynamic substance are the main obstacles to the modernization of Chinese medicine. The rich ingredient of Chinese medicine is almost attention, with a research strategy of forward pharmacology. This strategy often neglects the study of trace components of Chinese medicine. Synthetic lethality, a extremely complex gene interactions, is to magnify the effects of the co-regulation of biological effects（〉 1 000 times）. The theory of synthetic lethality has achieved good results in the development of anti-tumor drugs, including the discovery of PARP inhibitors, the clinical use of chemotherapy drug addition and attenuation combination. In view of this, this research model may be used to elucidate trace effective substance. Based on the reverse thinking of ＂targetcomponent-effect＂ and clear synergistic targets, the mechanism of traces and weak-potency substance of traditional Chinese medicine was studied, and the synergistic combination of potential was found.